Antibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 66733-1-Ig - Provider product page
- Provider
- Proteintech Group
- Product name
- RHOA antibody
- Antibody type
- Monoclonal
- Description
- RHOA antibody (Cat. #66733-1-Ig) is a mouse monoclonal antibody that shows reactivity with Human, mouse, pig, rat and has been validated for the following applications: IF, IHC, WB,ELISA.
- Reactivity
- Human, Mouse, Rat, Porcine
- Host
- Mouse
- Conjugate
- Unconjugated
- Isotype
- IgG
- Antibody clone number
- 1B3D7
- Vial size
- 20ul, 150ul
Submitted references CUX1 Facilitates the Development of Oncogenic Properties Via Activating Wnt/β-Catenin Signaling Pathway in Glioma.
GTPBP2 positively regulates the invasion, migration and proliferation of non-small cell lung cancer.
Mirtronic miR-4646-5p promotes gastric cancer metastasis by regulating ABHD16A and metabolite lysophosphatidylserines.
The long noncoding RNA KTN1-AS1 promotes bladder cancer tumorigenesis via KTN1 cis-activation and the consequent initiation of Rho GTPase-mediated signaling.
RALY may cause an aggressive biological behavior and a dismal prognosis in non-small-cell lung cancer.
Feng F, Zhao Z, Zhou Y, Cheng Y, Wu X, Heng X
Frontiers in molecular biosciences 2021;8:705008
Frontiers in molecular biosciences 2021;8:705008
GTPBP2 positively regulates the invasion, migration and proliferation of non-small cell lung cancer.
Jie L, Cong L, Conghui W, Ying G
Journal of Cancer 2021;12(13):3819-3826
Journal of Cancer 2021;12(13):3819-3826
Mirtronic miR-4646-5p promotes gastric cancer metastasis by regulating ABHD16A and metabolite lysophosphatidylserines.
Yang L, Hou Y, Du YE, Li Q, Zhou F, Li Y, Zeng H, Jin T, Wan X, Guan S, Wang R, Liu M
Cell death and differentiation 2021 Sep;28(9):2708-2727
Cell death and differentiation 2021 Sep;28(9):2708-2727
The long noncoding RNA KTN1-AS1 promotes bladder cancer tumorigenesis via KTN1 cis-activation and the consequent initiation of Rho GTPase-mediated signaling.
Hu X, Xiang L, He D, Zhu R, Fang J, Wang Z, Cao K
Clinical science (London, England : 1979) 2021 Feb 12;135(3):555-574
Clinical science (London, England : 1979) 2021 Feb 12;135(3):555-574
RALY may cause an aggressive biological behavior and a dismal prognosis in non-small-cell lung cancer.
Song G, Guo G, Du T, Li X, Wang J, Yan Y, Zhao Y
Experimental cell research 2020 Apr 15;389(2):111884
Experimental cell research 2020 Apr 15;389(2):111884
No comments: Submit comment
No validations: Submit validation data